Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.33 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4669410 | 0.82 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CTSDCTSL | |
| SCHEMBL6692478 | 0.82 | HDAC6 (0.36) | HDAC6HDAC1HDAC2KCNQ4KCNQ5 | |
| SCHEMBL1207293 | 0.82 | CA14 (0.39) | HDAC6HDAC1HDAC2KCNQ4KCNQ5 | |
| SCHEMBL21069899 | 0.81 | HDAC6 (0.33) | HDAC6HDAC1HDAC2CTSDCTSL | |
| SCHEMBL4726104 | 0.80 | DPP4 (0.49) | HDAC6HDAC1HDAC2CTSDCTSL | |
| SCHEMBL30897721 | 0.78 | HDAC6 (0.34) | HDAC6HDAC1HDAC2KCNQ4KCNQ5 | |
| SCHEMBL25794066 | 0.78 | CTSK (0.38) | HDAC6HDAC1HDAC2CTSDCTSL | |
| SCHEMBL1980562 | 0.78 | KDM4E (0.36) | HDAC6HDAC1HDAC2CTSDCTSL | |
| SCHEMBL18623439 | 0.77 | CHRM1 (0.38) | HDAC6HDAC1HDAC2CTSDCTSL | |
| SCHEMBL3530471 | 0.77 | CA14 (0.36) | HDAC6HDAC1HDAC2KCNQ4KCNQ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 310 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4003988-B1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | SERVIER LAB (FR) | 2026-05-20 | — | — | EP | disclosed |
| US-12624044-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260103453-A1 | NOVEL PYRIMIDINE DERIVATIVE AS BRUTON'S TYROSINE KINASE INHIBITOR | HANMI PHARMACEUTICAL CO LTD (KR) | 2026-04-16 | — | — | US | disclosed |
| US-12570648-B2 | 6,7-dihydro-5H-pyrido[2,3-c]pyridazine derivatives and related compounds as Bcl-xL protein inhibitors and pro-apoptotic agents for treating cancer | LES LABORATOIRES SERVIER (FR) | 2026-03-10 | — | — | US | disclosed |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2026-01-29 | — | — | US | disclosed |
| EP-4653049-A2 | CGRP ANTAGONIST COMPOUNDS | Nxera Pharma UK Limited (GB) | 2025-11-26 | — | — | EP | disclosed |
| WO-2025235686-A1 | FLUOROCAMPTOTHECIN COMPOUNDS, CONJUGATES, AND METHODS THEREOF | Aarvik Therapeutics, Inc. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20050009845-A1 | Thienopyrimidine compounds as protein tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-01-13 | — | — | US | disclosed |
| EP-1463507-A1 | THIENOPYRIMIDINE COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003053446-A1 | THIENOPYRIMIDINE COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-07-03 | — | — | WO | disclosed |
| EP-1157019-B1 | 4-ALKENYL (AND ALKYNYL) OXINDOLES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES, IN PARTICULAR CDK2 | HOFFMANN LA ROCHE (CH) | 2003-03-19 | — | — | EP | disclosed |
| CN-1330647-A | 4-alkenyl (and alkynyl) oxindoles as inhibitors of cell cycle protein dependent kinases, in particular CDK2 | HOFFMANN LA ROCHE (CH) | 2002-01-09 | — | — | CN | disclosed |
| EP-1157019-A1 | 4-ALKENYL (AND ALKYNYL) OXINDOLES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES, IN PARTICULAR CDK2 | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-28 | — | — | EP | disclosed |
| US-6303793-B1 | INTERMEDIATES FOR CYCLIN-DEPENDENT KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2001-10-16 | — | — | US | disclosed |
| US-6252086-B1 | CYCLIN-DEPENDENT KINASES INHIBITORS; ANTICANCER AGENTS | HOFFMANN-LA ROCHE INC. | 2001-06-26 | — | — | US | disclosed |
| US-6130239-A | INHIBIT CYCLIN-DEPENDENT KINASES | HOFFMANN-LA ROCHE INC. (US) | 2000-10-10 | — | — | US | disclosed |
| WO-2000035908-A1 | 4-ALKENYL (AND ALKYNYL) OXINDOLES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES, IN PARTICULAR CDK2 | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | HDAC6 523/4885HDAC1 183/4885HDAC2 155/4885 |
| US-20050009845-A1 | Thienopyrimidine compounds as protein tyrosine kinase inhibitors | ERBB2, ERBB4, ERBB3 | HDAC6 4049/4885HDAC1 3439/4885HDAC2 3693/4885 |
| US-20260027220-A1 | EPHA2 BCL-XL INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOF | EPHA2, EPHA1, EPHB1 | HDAC6 2462/4885HDAC1 4158/4885HDAC2 4186/4885 |
| US-20260103453-A1 | NOVEL PYRIMIDINE DERIVATIVE AS BRUTON'S TYROSINE KINASE INHIBITOR | BTK, LYN, LCK | HDAC6 1414/4885HDAC1 1479/4885HDAC2 1173/4885 |
| US-12570648-B2 | 6,7-dihydro-5H-pyrido[2,3-c]pyridazine derivatives and related compounds as Bcl-xL protein inhibitors and pro-apoptotic agents for treating cancer | BCOR, BCL2A1, BAK1 | HDAC6 2847/4885HDAC1 671/4885HDAC2 1912/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | HDAC6 238/4885HDAC1 126/4885HDAC2 70/4885 |
| US-12624044-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCC1, SMARCA2 | HDAC6 336/4885HDAC1 125/4885HDAC2 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.